Persistent organ dysfunction after severe sepsis: A systematic review

Journal of Critical Care

Volumn 29, Issue 3, 2014, Pages 320-326

  Guirgis, Faheem W ^a   Khadpe, Jay D ^b   Kuntz, Gretchen M ^a   Wears, Robert L ^a   Kalynych, Colleen J ^a   Jones, Alan E ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Long term organ dysfunction; Long term outcomes; Organ dysfunction; Organ failure; Sepsis survival; Septic shock; Severe sepsis

Indexed keywords

ANTIINFECTIVE AGENT; ENDOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; MURINE MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR ALPHA; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR P55 FUSION PROTEIN; ULINASTATIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; GASTROINTESTINAL DISEASE; GRAM NEGATIVE SEPSIS; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PERSISTENT ORGAN DYSFUNCTION; PREVALENCE; REMISSION; RESUSCITATION; SEPSIS; SEPTIC SHOCK; SURVIVAL; SYSTEMATIC REVIEW; ADULT; AGED; ANTIBODY SPECIFICITY; CENTRAL NERVOUS SYSTEM DISEASES; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME, ADULT; TIME;

ADULT; AGED; CENTRAL NERVOUS SYSTEM DISEASES; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; ORGAN SPECIFICITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; TIME FACTORS;

EID: 84899957725     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2013.10.020     Document Type: Article

References (26)

1. Strehlow M.C., Emond S.D., Shapiro N.I., et al. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006, 48:326-331. [331.e1-3].
2. Angus D.C., Wax R.S. Epidemiology of sepsis: an update. Crit Care Med 2001, 29:S109-S116.
3. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the united states from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
4. Lagu T., Rothberg M.B., Shieh M.S., et al. Hospitalizations, costs, and outcomes of severe sepsis in the united states 2003 to 2007. Crit Care Med 2012, 40:754-761.
5. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the united states: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
6. Puskarich M.A., Trzeciak S., Shapiro N.I., et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011, 39:2066-2071.
7. Jones A.E., Brown M.D., Trzeciak S., et al. The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: a meta-analysis. Crit Care Med 2008, 36:2734-2739.
8. Jones A.E., Shapiro N.I., Trzeciak S., et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010, 303:739-746.
9. Dellinger R.P., Levy M.M., Rhodes A., et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39(2):165-228.
10. Kumar G., Kumar N., Taneja A., et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011, 140(5):1223-1231.
11. Winters B.D., Eberlein M., Leung J., et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010, 38:1276-1283.
12. Poulsen J.B., Moller K., Kehlet H., et al. Long-term physical outcome in patients with septic shock. Acta Anaesthesiol Scand 2009, 53:724-730.
13. Karlsson S., Ruokonen E., Varpula T., et al. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009, 37:1268-1274.
14. Hofhuis J.G., Spronk P.E., van Stel H.F., et al. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg 2008, 107:1957-1964.
15. Korosec Jagodic H., Jagodic K., Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care 2006, 10:R134.
16. Heyland D.K., Hopman W., Coo H., et al. Long-term health-related quality of life in survivors of sepsis. short form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28:3599-3605.
17. Sacanella E., Perez-Castejon J.M., Nicolas J.M., et al. Functional status and quality of life 12 months after discharge from a medical ICU in healthy elderly patients: a prospective observational study. Crit Care 2011, 15:R105.
18. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
19. West S., King V., Carey T.S., et al. Systems to rate the strength of scientific evidence. Evid. Rep. Technol. Assess. (Summ.) 2002, 47:1-11.
20. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
21. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
22. Bone R.C., Balk R.A., Fein A.M., et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995, 23:994-1006.
23. Cohen J., Carlet J. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. international sepsis trial study group. Crit Care Med 1996, 24:1431-1440.
24. Abraham E., Glauser M.P., Butler T., et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. ro 45-2081 study group. JAMA 1997, 277:1531-1538.
25. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet 1998, 351:929-933.
26. Chen H., He M.Y., Li Y.M. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. Chin Med J 2009, 122:883-888.